ReviewInternational journal of cardiology. Congenital heart disease2022
Protein-losing enteropathy in Fontan circulation: Pathophysiology, outcome and treatment options of a complex condition.
Review in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation.Pediatric cardiology · 2026Trial
- Impact of Respiratory Mechanics on Venous Return in Single Ventricle Physiology: A Clinical Imaging Study.JACC. Basic to translational science · 2026Article
- Fontan Failure: Current State of the Art in Mechanical Circulatory Support and Transplantation.Children (Basel, Switzerland) · 2026Review
- Intermittent Levosimendan Administration for Advanced Heart Failure Treatment in Adults with Congenital Heart Disease (Levo-ACHD Study).Medicina (Kaunas, Lithuania) · 2026Article
- Long-Term Care in Fontan Circulation: Surveillance and Management of Fontan-Associated Liver Disease and Protein-Losing Enteropathy.Current cardiology reports · 2026Review
- Reduced Perfusion Pressure as a Predictor of Protein-Losing Enteropathy After Fontan Procedure: Beyond Central Venous Pressure.Pediatric cardiology · 2026Article
- Functionally Single-Ventricle Complications After Fontan Palliation-A Narrative Review.Journal of clinical medicine · 2026Review
- Clinical improvement of protein-losing enteropathy after SGLT2 inhibitor therapy in an adult with failing Fontan circulation: a case report.European heart journal. Case reports · 2026Article
- Association Between Hemodynamic Parameters and Gut Microbiota in Fontan Circulation: A Cross-Sectional Study.Journal of the American Heart Association · 2026Article
- The fate of the Fontan circulation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Single Ventricle Fontan: The Basics for General Cardiologists.Methodist DeBakey cardiovascular journal · 2026Review
- Liver Imaging in Fontan Patients: How Does Ultrasound Compare to Cross-Sectional Imaging?JACC. Advances · 2024Article
- Protein-Losing Enteropathy in the Failing Fontan: Treatment With Angiotensin Receptor Neprilysin Inhibitor.JACC. Case reports · 2024Article
- Intraperitoneal Corticosteroid Injection for Refractory Ascites in a Patient with Fontan Circulation.Acta Cardiologica Sinica · 2024Article
- Predictors of protein losing enteropathy after Fontan completion: An 8-year retrospective study at Sheikh Khalifa Medical City.Global cardiology science & practice · 2023Article
- Current diagnostic and therapeutic strategies for the management of lymphatic insufficiency in patients with hypoplastic left heart syndrome.Frontiers in pediatrics · 2023Review
- Editor's corner & issue at a glance.International journal of cardiology. Congenital heart disease · 2022Article
- Optimal Fenestration of the Fontan Circulation.Frontiers in physiology · 2022Article
- Protein-losing enteropathy after the Fontan procedure - A cardiologist's and gastroenterologist's perspective.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-losing enteropathy (PLE) represents a rare but severe and potentially life-threatening complication following Fontan operation in patients with a functional single ventricle. PLE is characterized by enteric protein loss, leading to devastating multiorgan involvement with increased morbidity and mortality. In spite of remarkable advances in the care of congenital heart disease in recent years, treatment of PLE is still one of the most challenging tasks due to limited understanding of the underlying mechanisms and lack of high-quality evidence from large scale, controlled studies to test the real efficacy of the several treatment strategies, which have been proposed. For this reason, we herewith aim to discuss the pathogenesis and diagnosis of PLE in Fontan patients as well as provide a comprehensive overview on potential advantages and disadvantages of the currently available therapeutic strategies, in order to propose a stepwise approach for the management of this unique condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.